Antihistamines OTC Switch Battle Moves To Capitol Hill
This article was originally published in The Tan Sheet
Executive Summary
A House subcommittee will examine FDA's legal authority to initiate an Rx-to-OTC switch without the sponsor's consent during a June 13 hearing.
You may also be interested in...
Allergy Drugs Forced OTC Switch Not Unconstitutional "Taking" - WellPoint
An FDA-mandated OTC switch of second-generation antihistamines would not result in an unconstitutional "deprivation of property" for drug marketers, WellPoint Health Networks says in comments to FDA.
PhRMA Defends 30-Month ANDA Stay In McCain/Schumer Position Paper
The brand vs. generic industry positioning surrounding proposed Hatch/Waxman process reforms includes conflicting arguments over the potential for standard intellectual property procedures to protect pharmaceutical companies from patent infringement.
Second-Generation Antihistamine OTC Labeling Could Resemble Monograph
OTC labeling for second-generation antihistamines - if the drugs were to switch - may not differ greatly from warnings on existing nonprescription allergic rhinitis symptom relief drugs.